Why some lung cancer pills stop working over time
Original title: Clinical features and multidimensional prognostic model of EGFR-TKI acquired resistance in NSCLC patients with or without brain metastases.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This was a look back at patient records, not a test of a new treatment.
The short version
Doctors looked back at old patient records to see who stops responding to a common lung cancer pill.
What was studied. Doctors reviewed records of 186 people with non-small cell lung cancer. Some had cancer that had spread to the brain. All had taken a pill called an EGFR-TKI.
What they found. A few things made the pill more likely to stop working. These were certain gene changes, including TP53: A gene checked on the tumor tissue. Whether it has changed is one of the findings used to name an astrocytoma. Ask your team whether the change they found was in the tumor only. See the glossary and MET, and a high CEA blood test. Drugs that block new blood vessels lowered that risk. Survival was 14.0 months in the group whose pill stopped working, and 38.0 months in the other group. People with 3 or more brain tumors tended to do worse.
What this means, and what it doesn't
What it could mean: If your pill stops working, your doctor may look at your gene tests and blood tests. Those clues can help you both talk about what to try next.
What it doesn't mean: This does not mean a new treatment is ready for you. It was a look back at records that already existed, not a trial. That kind of study can show links, but it cannot prove one thing caused another. It is not a cure, and it does not promise anyone more time.
Source: PubMed, September 12, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.